Checkpoint Therapeutics Q1 2024 Earnings Report $3.44 -0.22 (-6.01%) As of 04:00 PM Eastern Earnings HistoryForecast Checkpoint Therapeutics EPS ResultsActual EPS-$0.33Consensus EPS -$0.37Beat/MissBeat by +$0.04One Year Ago EPSN/ACheckpoint Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACheckpoint Therapeutics Announcement DetailsQuarterQ1 2024Date5/10/2024TimeN/AConference Call ResourcesCKPT Earnings History 3 golden rules for dividends (Ad)If you have any interest in building a great dividend portfolio, you will want to watch legend, Jack Carter’s briefing asap: The 3 Golden Rules for a Powerhouse Dividend Portfolio During this class, Jack walks you through all three of his “golden rules” and how they work. He even shares specific tickers that meet his criteria which you could consider adding to your portfolio today! And he explains each of his golden rules in detail.Just tap here to join the presentation. Checkpoint Therapeutics Earnings HeadlinesCheckpoint Therapeutics: Updating My Strategy After Unloxcyt's ApprovalDecember 18, 2024 | seekingalpha.comCheckpoint Therapeutics Upgraded to Buy Following FDA Approval and Increased Price TargetDecember 16, 2024 | markets.businessinsider.comDo this to position yourself after last month’s tech’s tumble… A lot of investors saw a significant portion of their portfolio erased after $1.7 trillion was wiped out of the Magnificent 7… Now they’re scratching their heads trying to figure out where to invest their money going forward. Well, you won’t need to search for long because the pullback from mega-cap tech is allowing other sectors and smaller companies to stand out… Setting up what could be a massive once-in-a-lifetime “double dip” opportunity on an often overlooked class of stocks. I’m talking about small cap stocks that pay dividends every month… January 7, 2025 | DTI (Ad)Checkpoint Therapeutics Gets Its First FDA ApprovalDecember 15, 2024 | marketwatch.comCheckpoint Therapeutics, Inc: Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT (cosibelimab-ipdl)December 14, 2024 | finanznachrichten.deCheckpoint Therapeutics Announces FDA Approval of UNLOXCYT(TM) (cosibelimab-ipdl)December 14, 2024 | stockhouse.comSee More Checkpoint Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Checkpoint Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Checkpoint Therapeutics and other key companies, straight to your email. Email Address About Checkpoint TherapeuticsCheckpoint Therapeutics (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.View Checkpoint Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Upcoming Earnings Schlumberger (1/17/2025)Procter & Gamble (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
